For example, BCL2 selective inhibitor ABT-199 has shown high efficacy in the treatment of chronic lymphocytic leukemia (CLL), but it cannot induce apoptosis in certain tumor cell lines with MCL1 amplification [25]. Here, MCL1 is linked to B-cell chronic lymphocytic leukemia.